EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N. Kumar, DM, Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-CP-08(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Cerebral Palsy is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Cerebral Palsy (CP) is a non-progressive neurological condition resulting from early brain injury or maldevelopment.
Biological Rationale & Paracrine Action:
Investigates the immunomodulatory and trophic paracrine potential of clinical-grade mesenchymal stem cells to support tissue homeostasis, cellular repair, and inflammatory moderation.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Target Candidate: Children and adults with diagnosed spastic, dyskinetic, ataxic, or mixed Cerebral Palsy (GMFCS Levels I–V).
Mandatory Pre-Procedure Diagnostics:
Mandatory Diagnostic Screening: Up-to-date brain MRI, recent EEG (to assess seizure activity), pediatric orthopedic spine/hip alignment evaluation, and complete blood profile.
Strict Safety Exclusion Parameters:
Active, unmanaged refractory epilepsy; severe progressive neurodegenerative disorders; active systemic infection; severe structural contractures requiring immediate orthopedic surgery.
Triage Protocol & Multi-Specialty Clearance:
Pre-travel multi-disciplinary medical board evaluation and baseline scan review prior to issuing medical visa invitation clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Spasticity & Tone: Reduction in muscle hypertonia, assisting ease of movement and daily handling.
- Motor Control: Better head control, sitting stability, balance, and gross motor functional milestones.
- Coordination & Reflexes: Modest gains in fine-motor grasping and reduction in involuntary movements.
- Speech & Feeding: Improved swallowing coordination, reduced drooling, and clearer vocalizations.
Documented Procedural Risks & Limits:
- Common temporary side effects: Low-grade fever, localized puncture soreness, or post-lumbar headache (resolving within 24–48 hours).
- No outcome guarantee: Functional improvement varies substantially based on patient age, baseline GMFCS level, and consistency of post-treatment rehabilitation.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Hospital Accreditation
Delivered exclusively within NABH- and JCI-accredited tertiary medical campuses.
Certified cGMP Laboratories
Cleanrooms compliant with CDSCO standards for sterility, viability, and cellular characterization.
Multidisciplinary Team
Dedicated pediatric neurologists, neurosurgeons, physiatrists, and pediatric rehabilitation therapists.
Transparent Ethics
Oversight by a registered Institutional Ethics Committee (IEC); no patient is accepted if clinical utility is not anticipated.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Teleconsult
Direct video consultation with the treating pediatric neurologist before booking.
Medical Visa Guidance
Official Indian Government Medical Visa (MED / MED-X for attendants) invitation letters and consular documentation support.
Dedicated Case Coordinator
Single point-of-contact liaison managing appointments, hospital admission, and translation needs.
Structured Post-Care
Telemedicine follow-ups at 1, 3, 6, and 12 months with reports shared directly with the patient's local home therapist.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Accessible Travel
Private wheelchair-accessible airport pick-up and drop-off.
Family Accommodations
Choice of private hospital suites with attendant beds or inspected, wheelchair-accessible partner apartments within 10 minutes of the hospital.
On-Ground Assistance
Local SIM card registration, currency exchange, and dietary meal accommodation (blended, pureed, allergen-free).
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 5 to 7 days comprehensive in-clinic stay.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Cerebral Palsy
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Landmark Double-Blind Randomized Controlled Trial on Autologous Cord Blood
Sun, J. M., Song, A. W., Case, L. E., Mikati, M. A., Gustafson, K. E., Simmons, R., Goldstein, R., Petry, J., McLaughlin, C., Cotten, C. M., Jasien, J., Zheng, N. X., Erickson, S., Banas, P., Bush, P., & Kurtzberg, J. (2017). Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial. Stem Cells Translational Medicine, 6(12), 2071–2078.
Double-Blind Placebo-Controlled Trial on Allogeneic Cord Blood Potentiated with Erythropoietin
Min, K., Song, J., Kang, J. Y., Ko, J., Ryu, J. S., Kang, M. S., Rhie, S. J., Kim, S. H., & Kim, M. (2013). Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells, 31(3), 581–591.
Randomized Double-Blind Trial on Human Umbilical Cord MSCs
Gu, J., Huang, L., Zhang, C., Wang, J., Zhang, R., Tu, Z., Wang, H., & Zhou, Z. (2020). Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Research & Therapy, 11(1), 43.
Clinical Trial on Autologous Bone Marrow Mononuclear Cells in Cerebral Palsy
Sharma, A., Gokulchandran, N., Sane, H., Nagrajan, A., Paranjape, A., Kulkarni, P., Shetty, A., Mishra, P., Kali, M., & Biju, H. (2014). Autologous bone marrow mononuclear cell transplantation in cerebral palsy: an open label, uncontrolled clinical trial. Journal of Stem Cell Research & Therapy, 4(4), 198.
Statutory Notice & Mandatory Regulatory Disclosure:
Regulatory Notice (ICMR / CDSCO Compliance): In accordance with the National Guidelines for Stem Cell Research issued by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT), stem cell therapy for Cerebral Palsy is classified as investigational. It is administered strictly as an adjunctive therapeutic protocol under Institutional Ethics Committee (IEC) oversight. It is not advertised as a standard cure or definitive medical treatment. Long-term progress relies heavily on continued, structured physical and occupational therapy.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.